Colorectal Cancer

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world. Worldwide incidence is expected to increase from 1.9 million cases diagnosed in 2020 to 3.1 million cases by 2040.





CRC forms in the tissues of the colon or rectum, often beginning as a growth called a polyp, which may form on the inner walls of the gastrointestinal system.

CRC is more common in men than women

1,066,000 866,000

Source: GLOBOCAN 2020

Median Age



At Diagnosis

At Death

Source: SEER 2014-2018

Common CRC Subtypes

Some cases of CRC are microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), which occurs when there are deficiencies in the cell's ability to repair DNA errors during cell division.

Patients with these subtypes often have a poor prognosis with lower survival rates.



Patients with advanced forms of CRC have fewer treatment options and lower survival rates.

About 4-5% of patients with metastatic CRC have MSI-H or dMMR tumors.

Kirsten rat sarcoma virus (KRAS) is one of the most frequently mutated oncogenes in human cancer. It acts as the "on-off switch" for cell growth and, when it is mutated, cells continuously generate, often developing into some of the most aggressive cancers.



KRAS genetic mutations drive cancer growth in up to 50% of patients with CRC.



One KRAS mutation, KRAS^{G12C}, occurs in approximately 3-4% of CRC cases.

Global Incidence

Estimated numbers of annual new CRC cases by region:

North America 180,600

Central America & the Caribbean 31,000

> South America 104,000

Europe 519,800

Africa 66,200


Oceania 20,700

1,009,400

Source: GLOBOCAN 2020

Staging & Survival Rates

The five-year relative survival rates for CRC vary depending on its stage and type:



Common Risk Factors





Physical Inactivity







Adults Ages 50+



Signs & Symptoms Unintended Weakness weight loss and fatigue Change in bowel Rectal bleeding habits (such as diarrhea & Cramping or constipation) abdominal pain

Treatment Options

A patient's treatment options are largely dependent on the stage of disease, and in some cases biomarkers, and may include:



Surgery



Targeted Therapy



Chemotherapy



Radiation Therapy



Immunotherapy

Blood in the stool